Latest Trials


EudraCT Number: 2022-003124-41 Sponsor Protocol Number: 219510 Start Date: 2023-03-27
Sponsor Name: GlaxoSmithKline Biologicals SA
Full Title: A non-randomized, open label, multi-country, cohort study to describe the safety of study participants who received RSVPreF3 maternal vaccination (any dose) or controls from previous RSV MAT studie...
Medical condition: Pregnancy related outcomes and events in maternal participants who were vaccinated against RSV or received control, and in their infants
Disease: Version SOC Term Classification Code Term Level
20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10070538 Gestational hypertension PT
20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036485 Pre-eclampsia PT
25.0 10036585 - Pregnancy, puerperium and perinatal conditions 10086971 Pre-eclampsia with severe features LLT
20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10070532 Fetal growth restriction LLT
20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10073024 Preterm premature rupture of membranes PT
21.1 10036585 - Pregnancy, puerperium and perinatal conditions 10075863 Preterm labor LLT
21.1 10036585 - Pregnancy, puerperium and perinatal conditions 10018210 Gestational diabetes mellitus LLT
20.0 100000004862 10008755 Chorioamnionitis LLT
21.1 10036585 - Pregnancy, puerperium and perinatal conditions 10041093 Small for gestational age LLT
21.1 10036585 - Pregnancy, puerperium and perinatal conditions 10067508 Low birth weight baby PT
21.1 10036585 - Pregnancy, puerperium and perinatal conditions 10067509 Very low birth weight baby LLT
21.1 10036585 - Pregnancy, puerperium and perinatal conditions 10074164 Extremely low birth weight baby LLT
20.1 10018065 - General disorders and administration site conditions 10011912 Death neonatal PT
25.0 10042613 - Surgical and medical procedures 10086969 Medically induced preterm birth PT
Population Age: Children, Adolescents, Under 18, Adults Gender: Female
Trial protocol: FI (Ongoing) BE (Ongoing) FR (Ongoing) ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-002389-33 Sponsor Protocol Number: CNTO1959CRD3007 Start Date: 2023-03-27
Sponsor Name: Janssen-Cilag International NV
Full Title: A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Crohn’s Disease After Surgical Resection
Medical condition: Crohn’s Disease After Surgical Resection
Disease: Version SOC Term Classification Code Term Level
20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Temporarily Halted) HU (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-002792-11 Sponsor Protocol Number: KAN0007 Start Date: 2023-03-27
Sponsor Name: Kancera AB
Full Title: KANDOVA - A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID) of KAND56...
Medical condition: Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
Population Age: Adults, Elderly Gender: Female
Trial protocol: NO (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003628-42 Sponsor Protocol Number: NBK182/1/2022 Start Date: 2023-03-24
Sponsor Name: Medical University of Gdańsk
Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome (LevoTako Trial)
Medical condition: Takotsubo syndrome (TTS), also known as apical ballooning syndrome, Takotsubo cardiomyopathy, broken heart syndrome, and stress-induced cardiomyopathy, is a rare condition and accounts for 1–3% of ...
Disease: Version SOC Term Classification Code Term Level
20.1 100000004849 10067676 Takotsubo syndrome LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: PL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-002959-18 Sponsor Protocol Number: PRN1008-017/ACT17125 Start Date: 2023-03-23
Sponsor Name: Principia Biopharma Inc
Full Title: An open label, two-arm, Phase 2a study to evaluate the effect of rilzabrutinib (PRN1008/SAR444671) on safety and disease activity in patients with IgG4-related disease
Medical condition: IgG4-related disease
Disease: Version SOC Term Classification Code Term Level
20.0 10028395 - Musculoskeletal and connective tissue disorders 10077271 Immunoglobulin G4 related disease PT
Population Age: Adults Gender: Male, Female
Trial protocol: ES (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2021-004849-20 Sponsor Protocol Number: 283PD201 Start Date: 2023-03-22
Sponsor Name: Biogen Idec Research Limited
Full Title: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease
Medical condition: Parkinson's Disease
Disease: Version SOC Term Classification Code Term Level
20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) FR (Ongoing) NL (Ongoing) AT (Ongoing) PL (Ongoing) IT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2023-000150-20 Sponsor Protocol Number: 1 Start Date: 2023-03-22
Sponsor Name: Bispebjerg-Frederiksberg Hospital
Full Title: The effect of exercise on pharmacodynamics and pharmacokinetics of a single dose of unfractionated heparin: A randomized, controlled, cross-over study
Medical condition: Unfractionated heparin is used for the prevention and treatment of deep vein thrombosis and complications hereof
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male
Trial protocol: DK (Completed)
Trial results: (No results available)

EudraCT Number: 2022-001796-14 Sponsor Protocol Number: CYTB323G12101 Start Date: 2023-03-20
Sponsor Name: Novartis Pharma AG
Full Title: An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus.
Medical condition: Systemic Lupus Erythematosus Lupus Nephritis
Disease: Version SOC Term Classification Code Term Level
21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-004079-17 Sponsor Protocol Number: COMBATARF Start Date: 2023-03-20
Sponsor Name: Rigshospitalet
Full Title: Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in mechanically ventilated patients with infectious pulmonary endotheliopathy – a multicentre randomized, placebo-controlled, b...
Medical condition: Infectious pulmonary endotheliopathy
Disease: Version SOC Term Classification Code Term Level
20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038696 Respiratory failure (excl neonatal) LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2022-002966-34 Sponsor Protocol Number: TAK-861-2002 Start Date: 2023-03-20
Sponsor Name: Takeda Development Center Americas, Inc.
Full Title: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2)
Medical condition: Narcolepsy without Cataplexy (Type 2)
Disease: Version SOC Term Classification Code Term Level
20.0 10029205 - Nervous system disorders 10028713 Narcolepsy PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NO (Completed) SE (Ongoing) FR (Ongoing) IT (Ongoing) ES (Ongoing) FI (Completed)
Trial results: (No results available)
3